



Genzyme Transgenics

SELECTED FINANCIAL DATA

SELECTED CONSOLIDATED FINANCIAL DATA (Dollars in thousands except per share data)

	<i>For the Fiscal Years Ended</i>				
	<i>January 2, 2000</i>	<i>January 3, 1999</i>	<i>December 28, 1997</i>	<i>December 29, 1996</i>	<i>December 31, 1995</i>
STATEMENT OF OPERATIONS DATA					
Net revenues	\$ 68,784	\$ 62,412	\$ 62,938	\$ 46,834	\$ 32,421
Operating costs and expenses	85,608	80,778	71,290	54,087	40,276
Operating loss from continuing operations	(16,824)	(18,366)	(8,352)	(7,253)	(7,855)
Loss from continuing operations	(18,761)	(19,590)	(9,343)	(7,746)	(5,704)
Discontinued operations	-	-	-	-	1,571
Net loss available to common shareholders	(20,258)	(20,746)	(9,343)	(7,746)	(4,133)
Net loss per common share (basic and diluted)	(1.02)	(1.15)	(0.54)	(0.52)	(0.35)
Weighted average number of shares outstanding (basic and diluted)	19,876,904	17,978,677	17,253,292	14,801,725	11,788,542

	<i>As of</i>					
	<i>Pro Forma (1) January 2, 2000 (unaudited)</i>	<i>January 2, 2000</i>	<i>January 3, 1999</i>	<i>December 28, 1997</i>	<i>December 29, 1996</i>	<i>December 31, 1995</i>
BALANCE SHEET DATA						
Cash and cash equivalents	\$ 67,202	\$ 7,782	\$ 11,740	\$ 6,383	\$ 8,894	\$ 5,825
Working capital (deficit)	61,303	(13,867)	(4,319)	(8,423)	(116)	(7,011)
Total assets	143,732	84,312	83,337	70,980	66,704	58,042
Long-term liabilities	14,676	14,676	10,397	10,779	6,742	7,179
Stockholders' equity	101,335	26,165	36,204	27,378	35,204	27,288

There were no cash dividends paid for any period presented.

(1) Pro Forma adjustment reflects the issuance of 4,025,000 shares of common stock at \$20.00 per share less offering expenses as well as the full pay down of the Company's revolving bank line of credit in the amount of \$15,750,000.